We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how patients will respond to new and existing treatments for inflammatory diseases such as multiple sclerosis (MS) and psoriasis.